Earth Science Tech (OTC: ETST), a strategic holding company building value by acquiring and actively managing operating businesses in pharmaceuticals, telemedicine, healthcare services, real estate, and select consumer markets, continues to redefine its vertically integrated market position while advancing technical innovation. Through its proprietary tech, along with its understanding of the market, where it is able to identify unique opportunities, the company is steadily growing its market share, tapping into markets that are projected to grow tremendously over the coming years.
ETST has positioned itself within the rapidly evolving telehealth industry, a market that is projected to be valued at $251.5 billion by 2030, reflecting a CAGR of 11.3% between 2025 and 2030 (https://ibn.fm/EiRW6). Through its investments into subsidiaries including DOConsultations LLC and Las Villas Health Care Inc., the company now offers both online and brick-and-mortar telehealth healthcare services, specializing in wellness health and services, as well as direct-to-patient delivery through partner pharmacies.
ETST is also capitalizing on the surging demand of peptide therapies, an industry that is currently estimated at $164 billion, projected to hit $249.6 billion by 2033, representing a CAGR of 8.7%. North America alone commands 61.9% of the global revenue share, and is a market ETST is tapping into with its telehealth services (https://ibn.fm/Jq8Z8).
The success of these services will be built on the company’s proprietary tech and IT infrastructure. ETST’s in-house IT team is known for building custom tech stacks from scratch, a strength that has made the company known for its tailored solutions that optimize operational efficiency and improve profit margins across all of its divisions. This represents a significant competitive edge for the company, and one that allows it to deliver value to its customers, while stamping its position as a leader in the market.
ETST has an unmatched fully integrated doctor network, dubbed MyOnlineConsultation.com, delivering both technology and clinical staffing solutions to digital health companies (https://ibn.fm/bU8E6). Parties interested in the service gain access to turnkey technology, a scalable platform handling live video and consultations, engineered to sync data seamlessly between providers and pharmacies. They also gain access to a credentialed network of licensed prescribers, coupled with direct routing to the pharmacy of their choice.
For more information, visit the company’s website at www.EarthScienceTech.com.
NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
mRNA vaccines and therapies have had a profound effect on the way various diseases, including…
VERAXA Biotech and Secarna Pharmaceuticals have reported an initial in vitro proof of concept for…
Researchers are developing new regenerative approaches, including stem cells, 3D-printed scaffolds and smart biomaterials designed…
A recent study has found that patients diagnosed with glioblastoma, a deadly brain cancer, can…
A new study whose results are yet to be peer-reviewed has shown that a personalized mRNA…
The company combines proprietary imaging hardware, FDA-cleared AI applications, cloud software, radiology services and healthcare…